Search results
Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS
Clinical Trials Arena via Yahoo Finance· 6 days agoThe study met its co-primary endpoints at a preplanned three-year...PFS with the ADCETRIS regimen....
Brighton Fringe Review: JOHN HINTON: WELL WELL WELL . . ., Komeida Studio
Broadway World· 4 days agoJohn Hinton: Well Well Well . . . is a musical show that has Hinton using songs and the story of his...
Bucoda Mayor and longtime firefighter Rob Gordon, 42, dies after battle with stomach cancer
The Chronicle, Centralia, Wash. via Yahoo News· 4 days agoJun. 4—Nearly eight months after he announced his diagnosis of stage 4 stomach cancer last November, Bucoda Mayor Rob Gordon, 42, died in the afternoon on June 3& ...
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Zacks via Yahoo Finance· 5 days agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 4 days agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...
ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy
FierceBiotech· 4 days agoThis year’s American Society of Clinical Oncology (ASCO) conference in Chicago marked a return to...
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 6 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
From stable to sanctuary: Dragonfly Foundation opens Farmer Family Dragonfly Center: PHOTOS -...
The Business Journals· 2 days agoThe 3,100-square-foot carriage house, situated on the Dragonfly Foundation’s property at 506 Oak...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 7 days ago-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles